XML 41 R3.htm IDEA: XBRL DOCUMENT
v3.25.0.1

Award Timing Disclosure | 12 Months Ended |  |
--- | --- | --- | ---
Dec. 31, 2024 | Apr. 29, 2024 USD ($) $ / shares | Jan. 31, 2024 USD ($) $ / shares
Award Timing Disclosures [Line Items] |  |  |
Award Timing MNPI Disclosure | Policies and Practices Related to the Timing of Equity Awards – 2024 Awards While we do not have a formal written policy in place with regard to the timing of awards of SARs or similar awards in relation to the disclosure of material nonpublic information, our equity awards are generally granted on fixed dates determined in advance. Annual equity awards are typically granted to our executives in late January or early February each year. On limited occasions, the Committee may grant equity awards outside of our annual grant cycle for new hires, promotions, recognition, retention or other purposes. The Committee’s general practice, and its practice for fiscal year 2024, has been to complete its annual executive compensation review and determine performance goals and target compensation for our executives, which coincides with the Company’s regularly scheduled Board meetings; then equity awards are granted with an effective date on the second full trading day following release of the Company’s fourth quarter earnings. For fiscal year 2025, the Committee granted equity awards in January 2025 effective as of the third full trading day following the release of the Company’s fourth quarter earnings and plans to continue this practice with respect to future grants. The Committee approves all equity award grants on or before the grant date and does not grant equity awards in anticipation of the release of material nonpublic information. Similarly, the Committee does not time the release of material nonpublic information based on equity award grant dates. Generally, the Committee uses the Company’s three-month average stock price as of the grant date and a valuation model estimation to determine the number of SARs granted. As set forth in the table below pursuant to Item 402(x)(2) of Regulation S-K, in 2024, the Committee granted SARs to the named executive officers with an effective date on the second full trading day following release of the Company’s quarterly earnings. The SARs have a ten-year term and an exercise price equal to the fair market value of the Company’s common shares on the date of grant. Consistent with the terms of the 2020 Stock Incentive Plan, the exercise price for each such award is the closing trading price of the Company’s common stock on the NYSE on the grant date.
Name |  |  |  | Grant date |  |  |  |  | Number of securities underlying the award |  |  | Exercise price of the award ($/Sh) |  |  |  | Grant date fair value of the award |  |  |  |  | Percentage change in the closing market price of the securities underlying the award between the trading day ending immediately prior to the disclosure of material nonpublic information and the trading day beginning immediately following the disclosure of material nonpublic information |
Samuel N. Hazen |  |  |  | 1/31/2024 |  |  |  |  | 79,784 |  |  | $304.90 |  |  |  | $8,158,720 |  |  |  |  | 5.18% |
William B. Rutherford |  |  |  | 1/31/2024 |  |  |  |  | 20,634 |  |  | $304.90 |  |  |  | $2,110,035 |  |  |  |  | 5.18% |
Michael A. Marks |  |  |  | 1/31/2024 |  |  |  |  | 5,503 |  |  | $304.90 |  |  |  | $  562,737 |  |  |  |  | 5.18% |
|  |  |  | 4/29/2024 |  |  |  |  | 9,096 |  |  | $311.42 |  |  |  | $1,003,379 |  |  |  |  | (2.37%) |
Jon M. Foster |  |  |  | 1/31/2024 |  |  |  |  | 20,634 |  |  | $304.90 |  |  |  | $2,110,035 |  |  |  |  | 5.18% |
Michael R. McAlevey |  |  |  | 1/31/2024 |  |  |  |  | 11,005 |  |  | $304.90 |  |  |  | $1,125,372 |  |  |  |  | 5.18% |
|  |  |  | 4/29/2024 |  |  |  |  | 2,274 |  |  | $311.42 |  |  |  | $  250,845 |  |  |  |  | (2.37%) |
Michael S. Cuffe, M.D. |  |  |  | 1/31/2024 |  |  |  |  | 12,656 |  |  | $304.90 |  |  |  | $1,294,204 |  |  |  |  | 5.18% |
Award Timing Method | The Committee’s general practice, and its practice for fiscal year 2024, has been to complete its annual executive compensation review and determine performance goals and target compensation for our executives, which coincides with the Company’s regularly scheduled Board meetings; then equity awards are granted with an effective date on the second full trading day following release of the Company’s fourth quarter earnings. For fiscal year 2025, the Committee granted equity awards in January 2025 effective as of the third full trading day following the release of the Company’s fourth quarter earnings and plans to continue this practice with respect to future grants. |  |
Award Timing Predetermined | true |  |
Award Timing MNPI Considered | true |  |
MNPI Disclosure Timed for Compensation Value | false |  |
Awards Close in Time to MNPI Disclosures |  |  |
Underlying Security Market Price Change |  | (2.37) | 5.18
Samuel N. Hazen [Member] |  |  |
Awards Close in Time to MNPI Disclosures |  |  |
Name |  |  | Samuel N. Hazen
Underlying Securities |  |  | 79,784
Exercise Price | $ / shares |  |  | $ 304.9
Fair Value as of Grant Date |  |  | $ 8,158,720
William B. Rutherford [Member] |  |  |
Awards Close in Time to MNPI Disclosures |  |  |
Name |  |  | William B. Rutherford
Underlying Securities |  |  | 20,634
Exercise Price | $ / shares |  |  | $ 304.9
Fair Value as of Grant Date |  |  | $ 2,110,035
Michael A. Marks [Member] |  |  |
Awards Close in Time to MNPI Disclosures |  |  |
Name |  |  | Michael A. Marks
Underlying Securities |  | 9,096 | 5,503
Exercise Price | $ / shares |  | $ 311.42 | $ 304.9
Fair Value as of Grant Date |  | $ 1,003,379 | $ 562,737
Jon M. Foster [Member] |  |  |
Awards Close in Time to MNPI Disclosures |  |  |
Name |  |  | Jon M. Foster
Underlying Securities |  |  | 20,634
Exercise Price | $ / shares |  |  | $ 304.9
Fair Value as of Grant Date |  |  | $ 2,110,035
Michael R. McAlevey [Member] |  |  |
Awards Close in Time to MNPI Disclosures |  |  |
Name |  |  | Michael R. McAlevey
Underlying Securities |  | 2,274 | 11,005
Exercise Price | $ / shares |  | $ 311.42 | $ 304.9
Fair Value as of Grant Date |  | $ 250,845 | $ 1,125,372
Michael S. Cuffe, M.D [Member] |  |  |
Awards Close in Time to MNPI Disclosures |  |  |
Name |  |  | Michael S. Cuffe, M.D.
Underlying Securities |  |  | 12,656
Exercise Price | $ / shares |  |  | $ 304.9
Fair Value as of Grant Date |  |  | $ 1,294,204

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection x -Paragraph 2 -Subparagraph ii -Sentence D + Details
Name: | ecd_AwardExrcPrice
Namespace Prefix: | ecd_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | instant

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection x -Paragraph 2 -Subparagraph ii -Sentence E + Details
Name: | ecd_AwardGrantDateFairValue
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | instant

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection x -Paragraph 1 + Details
Name: | ecd_AwardTmgDiscLineItems
Namespace Prefix: | ecd_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection x -Paragraph 1 + Details
Name: | ecd_AwardTmgMethodTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection x -Paragraph 1 + Details
Name: | ecd_AwardTmgMnpiCnsdrdFlag
Namespace Prefix: | ecd_
Data Type: | xbrli:booleanItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection x -Paragraph 1 + Details
Name: | ecd_AwardTmgMnpiDiscTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection x -Paragraph 1 + Details
Name: | ecd_AwardTmgPredtrmndFlag
Namespace Prefix: | ecd_
Data Type: | xbrli:booleanItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection x -Paragraph 2 -Subparagraph ii -Sentence C + Details
Name: | ecd_AwardUndrlygSecuritiesAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:decimalItemType
Balance Type: | na
Period Type: | instant

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection x -Paragraph 2 -Subparagraph ii -Sentence A + Details
Name: | ecd_AwardsCloseToMnpiDiscIndName
Namespace Prefix: | ecd_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | instant

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection x -Paragraph 2 + Details
Name: | ecd_AwardsCloseToMnpiDiscTable
Namespace Prefix: | ecd_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection x -Paragraph 1 + Details
Name: | ecd_MnpiDiscTimedForCompValFlag
Namespace Prefix: | ecd_
Data Type: | xbrli:booleanItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection x -Paragraph 2 -Subparagraph ii -Sentence F + Details
Name: | ecd_UndrlygSecurityMktPriceChngPct
Namespace Prefix: | ecd_
Data Type: | xbrli:pureItemType
Balance Type: | na
Period Type: | instant

X
- Details
Name: | ecd_IndividualAxis=hca_SamuelNHazenMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_IndividualAxis=hca_WilliamBRutherfordMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_IndividualAxis=hca_MichaelAMarksMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_IndividualAxis=hca_JonMFosterMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_IndividualAxis=hca_MichaelRMcaleveyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_IndividualAxis=hca_MichaelSCuffeMdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |